Table 1.
Patient characteristics.
Table 2.
Normal tissue tolerance for HCC SBRT in 3 fractions.
Fig 1.
Dose distributions of the (a) VMAT, (b) CKoriginal, and (c) CKmodified plans (Case #2); the dose of 45 Gy in 3 fractions is prescribed to the red isodose line that covers the PTV.
The isodose line was shown in each case, with the colored lines corresponding to the following doses: red = 45 Gy, yellow = 35 Gy, green = 25 Gy, dark blue = 15 Gy, and orange = 10 Gy, respectively. The PTV, CI, and HI were “17.6 cc, 1.02, and 1.09” for VMAT, “17.7 cc, 1.12, and 1.13” for CKoriginal, and “5.3 cc, 1.18, and 1.12” for CKmodified plans, respectively. The critical normal liver volumes receiving < 15 Gy (clVD<15Gy) were 1236.9 cc for VMAT, 1233.6 for CKoriginal, and 1294.1 for CKmodified plans, respectively.
Fig 2.
DVHs for the VMAT (solid line), CKoriginal (dashed line), and CKmodified plan (dotted line) in Case #2.
The PTV (red), stomach (blue), normal liver (green) and esophagus (purple) are shown.
Table 3.
Summary of the VMAT and CK plan parameters (29 cases).
Fig 3.
Dosimetric indices of the VMAT (◆), CKoriginal (■), and CKmodified (▲) plans for all cases (n = 29 per group): (a) Conformity index; (b) Tumor coverage (%); (c) Normal liver volume receiving > 15 Gy (nlVD>15Gy).
Table 4.
Summary of normal liver volume receiving < 5–45 Gy.
Fig 4.
Average DVHs of the normal liver (excluding the GTV) in 29 HCC patients with the VMAT, CKoriginal and CKmodified plans.
The prescription dose for all plans was 45 Gy in 3 fractions.